| Primary |
| Premedication |
42.5% |
| Chemotherapy |
10.8% |
| Anaesthesia |
8.6% |
| Product Used For Unknown Indication |
8.1% |
| Breast Cancer |
5.9% |
| Pneumonia |
2.7% |
| Preoperative Care |
2.7% |
| Pilonidal Cyst |
2.2% |
| Prophylaxis |
2.2% |
| Sedation |
2.2% |
| Squamous Cell Carcinoma |
2.2% |
| Lung Disorder |
1.6% |
| Adenocarcinoma |
1.1% |
| Anaesthetic Premedication |
1.1% |
| Basal Cell Carcinoma |
1.1% |
| Endometrial Cancer |
1.1% |
| Lung Cancer Metastatic |
1.1% |
| Ovarian Cancer Metastatic |
1.1% |
| Prophylaxis Of Nausea And Vomiting |
1.1% |
| Squamous Cell Carcinoma Of Lung |
1.1% |
|
| Vomiting |
13.3% |
| Shock |
10.0% |
| Hot Flush |
6.7% |
| Sense Of Oppression |
6.7% |
| Sinus Bradycardia |
6.7% |
| Urticaria |
6.7% |
| Wheezing |
6.7% |
| Hypertension |
3.3% |
| Infusion Related Reaction |
3.3% |
| Infusion Site Reaction |
3.3% |
| Motor Dysfunction |
3.3% |
| Nausea |
3.3% |
| Neutropenia |
3.3% |
| Oxygen Saturation Decreased |
3.3% |
| Paraesthesia |
3.3% |
| Pruritus |
3.3% |
| Pruritus Generalised |
3.3% |
| Purpura |
3.3% |
| Rash |
3.3% |
| Rash Macular |
3.3% |
|
| Secondary |
| Premedication |
30.8% |
| Product Used For Unknown Indication |
29.5% |
| Lung Neoplasm Malignant |
5.3% |
| Gastrointestinal Carcinoma |
4.8% |
| Chemotherapy |
3.5% |
| Breast Cancer |
3.1% |
| Rectal Cancer |
2.6% |
| Renal Transplant |
2.6% |
| Transplant Rejection |
2.2% |
| Metastatic Bronchial Carcinoma |
1.8% |
| Pneumonia |
1.8% |
| Squamous Cell Carcinoma Of Lung |
1.8% |
| Status Epilepticus |
1.8% |
| Gastrooesophageal Reflux Disease |
1.3% |
| Hepatitis C |
1.3% |
| Lung Disorder |
1.3% |
| Osteosynthesis |
1.3% |
| Throat Cancer |
1.3% |
| Anaesthetic Premedication |
0.9% |
| Computerised Tomogram |
0.9% |
|
| Malaise |
13.2% |
| Pneumonia |
13.2% |
| Vomiting |
10.5% |
| Hyponatraemia |
7.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.3% |
| Paraesthesia |
5.3% |
| Pruritus |
5.3% |
| Sense Of Oppression |
5.3% |
| Wound Dehiscence |
5.3% |
| Anaphylactic Reaction |
2.6% |
| Anaphylactic Shock |
2.6% |
| Bronchospasm |
2.6% |
| Cardio-respiratory Arrest |
2.6% |
| Convulsion |
2.6% |
| Cyanosis |
2.6% |
| Dyspnoea |
2.6% |
| Hot Flush |
2.6% |
| Hypertension |
2.6% |
| Ischaemic Stroke |
2.6% |
| Lung Disorder |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
32.6% |
| Drug Use For Unknown Indication |
12.1% |
| Premedication |
9.6% |
| Breast Cancer |
7.4% |
| Ovarian Cancer |
5.3% |
| Hypertension |
4.3% |
| Gastrooesophageal Reflux Disease |
2.5% |
| Pain In Extremity |
2.5% |
| Pain Prophylaxis |
2.5% |
| Antibiotic Therapy |
2.1% |
| Asthma |
2.1% |
| Breast Cancer Metastatic |
2.1% |
| Depression |
2.1% |
| Diabetes Mellitus Insulin-dependent |
2.1% |
| Endocarditis Staphylococcal |
2.1% |
| Uterine Neoplasm |
2.1% |
| Metastatic Renal Cell Carcinoma |
1.8% |
| Prophylactic Chemotherapy |
1.8% |
| Lung Disorder |
1.4% |
| Lymphoma |
1.4% |
|
| Paraesthesia |
10.6% |
| Oxygen Saturation Decreased |
8.5% |
| Vomiting |
8.5% |
| Completed Suicide |
6.4% |
| Hypertension |
6.4% |
| Rash |
6.4% |
| Respiratory Distress |
6.4% |
| Toxicity To Various Agents |
6.4% |
| Laryngospasm |
4.3% |
| Nausea |
4.3% |
| Neuromyopathy |
4.3% |
| Rash Maculo-papular |
4.3% |
| Renal Tubular Necrosis |
4.3% |
| Toxic Skin Eruption |
4.3% |
| Ventricular Tachycardia |
4.3% |
| Cerebral Haematoma |
2.1% |
| Clostridium Difficile Colitis |
2.1% |
| Death |
2.1% |
| Encephalopathy |
2.1% |
| Endocarditis |
2.1% |
|
